UCSF Memory and Aging Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Geschwind, Michael
CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease

Hourglass Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease
Checkmark First biomarker data from trial for Huntington’s disease
Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease
Checkmark Safety data from P1/2 trial for Huntington’s disease
Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease
Recruiting
1/2
37
US
intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery
UniQure Biopharma B.V.
Huntington's Disease
04/29
06/29
Ljubenkov, Peter
INFRONT-3, NCT04374136 / 2019-004066-18: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia

Active, not recruiting
3
110
Europe, Canada, US, RoW
AL001, Placebo, Open label - AL001
Alector Inc.
Frontotemporal Dementia
09/25
10/27
ROCKIT-1, NCT04734379: Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Active, not recruiting
2a
15
US
Fasudil
Woolsey Pharmaceuticals
Progressive Supranuclear Palsy, Corticobasal Syndrome
11/22
11/23
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
INFRONT-2, NCT03987295 / 2019-000138-20: A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients

Completed
2
33
Europe, Canada, US
AL001
Alector Inc., GlaxoSmithKline
Frontotemporal Dementia
06/24
06/24
VandeVrede, Lawren
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25
Jacobs, Leslie M
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25
Yang, Xueyi
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
Leahy, Cara
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25

Download Options